BCDA BioCardia Future Price to Earnings

BioCardia Inc - graphic logo of issuer BCDA

The cardiology sector is currently constrained by lengthy FDA approval processes, leaving BioCardia, Inc. (BCDA) reliant on grants for survival. Revenues are based on cardiac cell therapy via CardiAMP systems, while sales of Helix catheters for ischemia provide a cash inflow from surgical centers. The company's forward P/E ratio demonstrates valuation dynamics, where the value 0.00 reflects the metric's balance at the current stage.

BCDA - biocardia.com Projected Price to Earnings over the range 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for BioCardia Inc (BCDA)

- stock quotes and analyst forecast:
Stock Price BioCardia|BCDA - Analyst Median Target
- market capitalization data:
Market Value BioCardia Inc.|BCDA - Total Enterprise Value
- balance sheet equity data:
Book Value per Share BioCardia|BCDA - Company Net Assets|Market Capitalization to Book Value Ratio biocardia.com|BCDA - Company Total Assets
- debt level and financial liquidity data:
Debt to Equity BioCardia, Inc.|BCDA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital BioCardia, Inc.|BCDA - Company Aggregate Debt|Debts to Book Capitalization BioCardia Inc.|BCDA - Long-Term Debt Volume|Company Short-Term Debts BioCardia|Quick Liquidity Indicator biocardia.com
- earnings and market ratios statistics:
BCDA - Final Profit|Projected Future Earnings BioCardia, Inc.|BCDA - Business Payback Period|Future Price to Earnings BioCardia, Inc|BCDA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple BioCardia Inc.|BCDA - Operating profit before deduction of amortization|Net earnings per share for the last 12 months BioCardia|BCDA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth biocardia.com|BCDA - Earnings per share growth in current year|Earnings growth forecast for next year BioCardia, Inc.
Summary company analytics:BioCardia
Signature product of BioCardia Inc

Driven by the unique CardiAMP system and inelastic patient demand, BioCardia, Inc. (BCDA) possesses exceptional pricing power within the myocardial therapy market. By analyzing the company's forward P/E ratio history, an investor assesses the relationship between current quotes and projected earnings, where low values may indicate either an undervalued asset or market skepticism regarding the business's ability to monetize its developments.

Main competitors

Forward P/E Multiple REGN|Market Cap to Projected Earnings iRhythm Technologies, Inc.|Future Price to Earnings Lantheus Medical Imaging LNTH|Mineralys Corp (MLYS) - Projected Price to Earnings Ratio|HeartFlow, Inc. - Forward P/E Multiple|kestramedical.com (KMTS) - Projected Price to Earnings|ESPR: Forward P/E Multiple|Amarin Corporation (AMRN) - Forward P/E Multiple|Future Price to Earnings Anteris|TNYA: Future Price to Earnings Multiple|Forward P/E Multiple CVRX|milestonepharma.com - Price to Future Earnings Ratio|Forward P/E Multiple CRDL (Cardiol Therapeutics Inc.)|Market Cap to Projected Earnings HeartBeam Inc (BEAT)|Tenax Therapeutics, Inc - Forward P/E Multiple|ADGM - Forward P/E Multiple|VTAK (Catheter Precision) - Projected Price to Earnings|ARCA Biopharma, Inc. - Future Price to Earnings Multiple|ACST (Acasti Pharma Inc) - Forward P/E Multiple|Aerovate Therapeutics Inc. (AVTE) - Market Cap to Projected Earnings|Future Price to Earnings Verve Therapeutics (VERV)|windtreetx.com - Price to Future Earnings Ratio